Commercial CVS obesity drug deal puts Lilly on equal footing with Novo BioPharma DiveThe agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.Metabolic & GLP-1Read full story pharminent May 28, 2026 (Last updated: May 28, 2026) BioPharma Dive The agreement includes Lilly s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: France ‘first EU country to cover obesity drugs’Next: GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’ Related Stories Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026 Commercial Lilly launches its LillyDirect sales channel in the UK pharminent June 25, 2026
